Dépôt numérique
RECHERCHER

Determination of urinary concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing medications to healthy subjects: Implications for doping control analysis of these stimulants banned in sport

Barroso, Osquel; Goudreault, Danielle; Carbó Banús, Marcel-lí; Ayotte, Christiane ORCID logoORCID: https://orcid.org/0000-0002-6352-2071; Mazzoni, Irene; Boghosian, Thierry et Rabin, Olivier (2012). Determination of urinary concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing medications to healthy subjects: Implications for doping control analysis of these stimulants banned in sport Drug Testing and Analysis , vol. 4 , nº 5. pp. 320-329. DOI: 10.1002/dta.291.

Ce document n'est pas hébergé sur EspaceINRS.

Résumé


Due to its stimulatory effects on the central nervous system, and its structural similarity to banned stimulants such as ephedrine and methamphetamine, pseudoephedrine (PSE) at high doses is considered as an ergogenic aid for boosting athletic performance. However, the status of PSE in the International Standard of the Prohibited List as established under the World Anti-Doping Code has changed over the years, being prohibited until 2003 at a urinary cut-off value of 25 μg/ml, and then subsequently removed from the Prohibited List during the period 2004-2009. The re-consideration of this position by the World Anti-Doping Agency (WADA) List Expert Group has led to the reintroduction of PSE in the Prohibited List in 2010. In this manuscript, we present the results of two WADA-sponsored clinical studies on the urinary excretion of PSE and its metabolite cathine (CATH) following the oral administration of different PSE formulations to healthy individuals at therapeutic regimes. On this basis, the current analytical urinary threshold for the detection of PSE as a doping agent in sport has been conservatively established at 150 μg/ml Copyright © 2011 John Wiley & Sons, Ltd. Results of two WADA-sponsored clinical excretion studies on the basis of which pseudoephedrine was re-introduced into the WADA Prohibited List 2010 as a substance banned in-competition (at a urinary threshold of 150 μg/mL.

Type de document: Article
Mots-clés libres: -
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 06 mars 2024 15:06
Dernière modification: 06 mars 2024 15:06
URI: https://espace.inrs.ca/id/eprint/13982

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice